"目錄號: HY-14658
Thalidomide能抑制由bFGF或VEGF誘導的體內血管生成。
相關產品
SBE-β-CD-MPTP hydrochloride-Cyclosporin A-Etomoxir-Auranofin-GKT137831-Ceruletide-Acetylcysteine-JC-1-BPTES-Brassinolide-FCCP-IPTG-MTT-RSL3 1S,3R--
生物活性
Description
Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo.IC50 value:Target:Thalidomide was commonly used therapeutically in the late 1950's; however, it was withdrawn from the market when it was discovered to cause birth defects. More recent research has found Thalidomide to affect key biochemical pathways yielding antiangiogenic and immunomodulatory activities. This compound has been shown to: selectively inhibit tumor necrosis factor-alpha (TNF alpha) biosynthesis and basic fibroblast growth factor (bFGF)-induced angiogenesis, induce apoptosis in human monocytes via a cytochrome c-dependent pathway, and to inhibit HIV-1 replication in a monocytoid (U1) line. These new found uses make Thalidomide an extremely valuable research tool.
Clinical Trial
IRCCS Policlinico S. Matteo
Hereditary Hemorrhagic Telangiectasia-Epistaxis
November 2011
Phase 2
Mayo Clinic-Celgene Corporation
Primary Sclerosing Cholangitis
April 2006
Phase 2
Sixth Affiliated Hospital, Sun Yat-sen University
Crohn Disease
October 2016
Early Phase 1
Xiao-Lin Yin-303rd Hospital of the People's Liberation Army
Thalassemia
May 2, 2017
Phase 2
Xiao-Lin Yin-303rd Hospital of the People's Liberation Army
Thalassemia
September 2016
Phase 2
Valme University Hospital-University of Seville
Hepatitis C
March 2009
Phase 2
M.D. Anderson Cancer Center-Celgene Corporation
Multiple Myeloma
May 1999
Phase 3
Johns Hopkins University
Idiopathic Pulmonary Fibrosis-Cough
December 2007
Phase 3
Steven P. Treon, MD, PhD-Dana-Farber Cancer Institute-Massachusetts General Hospital-Beth Israel Deaconess Medical Center-Brigham and Women's Hospital-Cape Cod Healthcare
Waldenstrom's Macroglobulinemia-Lymphoplasmacytic Lymphoma
May 2003
Phase 2
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Radiation Injuries
July 19, 2017
Phase 2
Henan Provincial Hospital
NSCLC
March 2016
Phase 4
Celgene Corporation
Multiple Myeloma
December 2001
Phase 2-Phase 3
Celgene Corporation
Multiple Myeloma
November 2013
Phase 1
The First Affiliated Hospital of Xiamen University
Hepatocellular Carcinoma-Recurrence
July 2013
University of Roma La Sapienza
Coronary Artery Disease
January 2014
Phase 4
National Institute of Neurology and Neurosurgery, Mexico-National Council of Science and Technology, Mexico
Refractory Epilepsy
June 2006
Phase 1-Phase 2
Medical University of Vienna
MALT Lymphoma
June 2006
Phase 2
Nanfang Hospital of Southern Medical University
Lymphoma, Large B-Cell, Diffuse
February 2017
Phase 3
Shanghai Jiao Tong University School of Medicine
Obscure Gastrointestinal Bleeding-Angiodysplasia-Gastric Antral Vascular Ectasia-Thalidomide
November 2004
Phase 2
M.D. Anderson Cancer Center-Celgene
Myeloma
August 2009
Phase 1-Phase 2
Fudan University
Hepatocellular Carcinoma
June 2009
Phase 3
Shanghai Jiao Tong University School of Medicine
Gastrointestinal Hemorrhage-Vascular Malformation
March 2010
Phase 2
China Medical University, China-The First Hospital of Liaoning Medical University-The First Affiliated Hospital of Dalian Medical University-The Second Affiliated Hospital of Dalian Medical University-Liaoning Tumor Hospital & Institute-Shengjing Hospital-General Hospital of Shenyang Military Region-Liaoyang Central Hospital-Third People's hospital Liaoyang-Petrochemical General Hospital of Liaoyang city-Anshan Tumor Hospital
Neoplasms
July 2014
Phase 3
University of North Carolina, Chapel Hill-Celgene Corporation
Endometriosis
October 2006
Phase 1
National Taiwan University Hospital
Hepatocellular Carcinoma
July 2006
Phase 2
Dartmouth-Hitchcock Medical Center-Celgene Corporation
Amyotrophic Lateral Sclerosis-ALS
February 2005
Phase 2
Grupo de Estudos Multicentricos em Onco-Hematologia
Multiple Myeloma
October 2003
Phase 3
University of Arkansas
Multiple Myeloma
February 1998
Phase 2
The Methodist Hospital System-Bayer
Prostatic Neoplasms
December 2006
Phase 2
Shanghai Pharmaceuticals Holding Co., Ltd
Ankylosing Spondylitis
February 2013
Phase 2
National Cancer Institute (NCI)
Recurrent Grade 1 Follicular Lymphoma-Recurrent Grade 2 Follicular Lymphoma-Recurrent Grade 3 Follicular Lymphoma-Recurrent Small Lymphocytic Lymphoma
July 2001
Phase 2
University of Arkansas-Celgene Corporation
Waldenstrom Macroglobulinemia
January 1999
Phase 2
Assistance Publique - H?pitaux de Paris
Sarcoidosis
February 2005
Phase 3
Memorial Sloan Kettering Cancer Center-Incyte Corporation-Celgene-M.D. Anderson Cancer Center
Myelofibrosis
February 27, 2017
Phase 2
Zhejiang Cancer Hospital
Metastatic Breast Cancer
October 2015
Phase 2
Shandong University-The Affiliated Hospital of the Chinese Academy of Military Medical Sciences-Anhui Medical University-The First Affiliated Hospital of Dalian Medical University-Shenzhen Second People's Hospital
Immune Thrombocytopenia
October 2013
Phase 2
M.D. Anderson Cancer Center-Celgene Corporation
Prostate Cancer
October 2000
Phase 1-Phase 2
Changzhou No.2 People's Hospital
Esophageal Cancer
January 2012
Phase 2
IRCCS Burlo Garofolo-Ospedale Meyer-Pediatric Gastroenterology Unit, IRCCS Gaslini, Genoa.-Vittore Buzzi Children's Hospital-University of Pisa-University of Messina-Università degli Studi di Brescia-University of Trieste
Inflammatory Bowel Diseases-Crohn's Disease-Ulcerative Colitis
August 2008
Phase 3
The Cleveland Clinic-Celgene Corporation
Gastrointestinal Hemorrhage-Portal Hypertension
May 2006
Phase 3
Case Comprehensive Cancer Center-National Cancer Institute (NCI)
Cancer
July 2002
Phase 1
First Affiliated Hospital, Sun Yat-Sen University
Crohn's Disease
January 2013
Phase 2
Hackensack University Medical Center-Millennium Pharmaceuticals, Inc.
Multiple Myeloma
April 2010
Phase 1-Phase 2
Norwegian University of Science and Technology-The Research Council of Norway-Nordic Myeloma Study Group, Germany
Multiple Myeloma
January 2002
Phase 3
Centre Hospitalier Universitaire, Amiens
Non Neoplastic Condition-Precancerous Condition
June 2007
Phase 2
Wake Forest University-Wake Forest University Health Sciences
Psoriasis, Plaque-type
April 2003
Phase 2
Celgene Corporation-Celgene
Multiple Myeloma
February 2003
Phase 3
National Cancer Institute (NCI)
